OX40 is a T cell receptor that boosts signaling in CD4+ and CD8+ T cells during various stages of immune response. Preclinical studies in mice have demonstrated the effectiveness of anti-OX40 antibodies as a single treatment and in combination with other immunotherapy approaches, such as
cancer vaccines. These antibodies are believed to work by activating OX40 in tumor-specific T cells to increase their sensitivity to tumor antigens and by engaging Fcγ receptors to selectively remove regulatory T cells within the tumor.
INCAGN01949 is a newly developed human IgG1 monoclonal antibody that targets OX40. It has been designed to enhance receptor signaling, leading to increased production of
TNFα and
IFNγ while reducing
IL-10. This is achieved through the clustering of OX40 and activation of the NFκB pathway in T cells. INCAGN01949 also has the ability to engage activating Fcγ receptors on immune cells, which could selectively target regulatory T cells within tumors.
The properties of INCAGN01949 suggest its potential for clinical development, both as a standalone treatment and in combination with other immunotherapies. The study was presented at the 107th Annual Meeting of the American Association for Cancer Research and published in the Cancer Research journal.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
